BACKGROUND: Height, a marker of childhood environmental exposures, is positively associated with prostate cancer risk, perhaps through the insulin-like growth factor system. We investigated the relationship of prostate cancer with height and its components (leg and trunk length) in a nested case-control study and with height in a dose-response meta-analysis. METHODS: We nested a case-control study within a population-based randomized controlled trial evaluating treatments for localized prostate cancer in British men ages 50 to 69 years, including 1,357 cases detected through prostate-specific antigen testing and 7,990 controls (matched on age, general practice, assessment date). Nine bibliographic databases were searched systematically for studies on the height-prostate cancer association that were pooled in a meta-analysis. RESULTS: Based on the nested case-control, the odds ratio (OR) of prostate-specific antigen-detected prostate cancer per 10 cm increase in height was 1.06 [95% confidence interval (95% CI): 0.97-1.16; p(trend) = 0.2]. There was stronger evidence of an association of height with high-grade prostate cancer (OR: 1.23; 95% CI: 1.06-1.43), mainly due to the leg component, but not with low-grade disease (OR: 0.99; 95% CI: 0.90-1.10). In general, associations with leg or trunk length were similar. A meta-analysis of 58 studies found evidence that height is positively associated with prostate cancer (random-effects OR per 10 cm: 1.06; 95% CI: 1.03-1.09), with a stronger effect for prospective studies of more advanced/aggressive cancers (random-effects OR: 1.12; 95% CI: 1.05-1.19). CONCLUSION: These data indicate a limited role for childhood environmental exposures-as indexed by adult height-on prostate cancer incidence, while suggesting a greater role for progression, through mechanisms requiring further investigation.
BACKGROUND: Height, a marker of childhood environmental exposures, is positively associated with prostate cancer risk, perhaps through the insulin-like growth factor system. We investigated the relationship of prostate cancer with height and its components (leg and trunk length) in a nested case-control study and with height in a dose-response meta-analysis. METHODS: We nested a case-control study within a population-based randomized controlled trial evaluating treatments for localized prostate cancer in British men ages 50 to 69 years, including 1,357 cases detected through prostate-specific antigen testing and 7,990 controls (matched on age, general practice, assessment date). Nine bibliographic databases were searched systematically for studies on the height-prostate cancer association that were pooled in a meta-analysis. RESULTS: Based on the nested case-control, the odds ratio (OR) of prostate-specific antigen-detected prostate cancer per 10 cm increase in height was 1.06 [95% confidence interval (95% CI): 0.97-1.16; p(trend) = 0.2]. There was stronger evidence of an association of height with high-grade prostate cancer (OR: 1.23; 95% CI: 1.06-1.43), mainly due to the leg component, but not with low-grade disease (OR: 0.99; 95% CI: 0.90-1.10). In general, associations with leg or trunk length were similar. A meta-analysis of 58 studies found evidence that height is positively associated with prostate cancer (random-effects OR per 10 cm: 1.06; 95% CI: 1.03-1.09), with a stronger effect for prospective studies of more advanced/aggressive cancers (random-effects OR: 1.12; 95% CI: 1.05-1.19). CONCLUSION: These data indicate a limited role for childhood environmental exposures-as indexed by adult height-on prostate cancer incidence, while suggesting a greater role for progression, through mechanisms requiring further investigation.
Authors: J R Cerhan; J C Torner; C F Lynch; L M Rubenstein; J H Lemke; M B Cohen; D M Lubaroff; R B Wallace Journal: Cancer Causes Control Date: 1997-03 Impact factor: 2.506
Authors: S O Andersson; J Baron; A Wolk; C Lindgren; R Bergström; H O Adami Journal: Cancer Epidemiol Biomarkers Prev Date: 1995 Apr-May Impact factor: 4.254
Authors: S O Andersson; A Wolk; R Bergström; H O Adami; G Engholm; A Englund; O Nyrén Journal: J Natl Cancer Inst Date: 1997-03-05 Impact factor: 13.506
Authors: Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan Journal: Cancer Causes Control Date: 2010-12-24 Impact factor: 2.506
Authors: Jack Cuzick; Mangesh A Thorat; Gerald Andriole; Otis W Brawley; Powel H Brown; Zoran Culig; Rosalind A Eeles; Leslie G Ford; Freddie C Hamdy; Lars Holmberg; Dragan Ilic; Timothy J Key; Carlo La Vecchia; Hans Lilja; Michael Marberger; Frank L Meyskens; Lori M Minasian; Chris Parker; Howard L Parnes; Sven Perner; Harry Rittenhouse; Jack Schalken; Hans-Peter Schmid; Bernd J Schmitz-Dräger; Fritz H Schröder; Arnulf Stenzl; Bertrand Tombal; Timothy J Wilt; Alicja Wolk Journal: Lancet Oncol Date: 2014-10 Impact factor: 41.316
Authors: Zsofia Kote-Jarai; Ali Amin Al Olama; Graham G Giles; Gianluca Severi; Johanna Schleutker; Maren Weischer; Daniele Campa; Elio Riboli; Tim Key; Henrik Gronberg; David J Hunter; Peter Kraft; Michael J Thun; Sue Ingles; Stephen Chanock; Demetrius Albanes; Richard B Hayes; David E Neal; Freddie C Hamdy; Jenny L Donovan; Paul Pharoah; Fredrick Schumacher; Brian E Henderson; Janet L Stanford; Elaine A Ostrander; Karina Dalsgaard Sorensen; Thilo Dörk; Gerald Andriole; Joanne L Dickinson; Cezary Cybulski; Jan Lubinski; Amanda Spurdle; Judith A Clements; Suzanne Chambers; Joanne Aitken; R A Frank Gardiner; Stephen N Thibodeau; Dan Schaid; Esther M John; Christiane Maier; Walther Vogel; Kathleen A Cooney; Jong Y Park; Lisa Cannon-Albright; Hermann Brenner; Tomonori Habuchi; Hong-Wei Zhang; Yong-Jie Lu; Radka Kaneva; Ken Muir; Sara Benlloch; Daniel A Leongamornlert; Edward J Saunders; Malgorzata Tymrakiewicz; Nadiya Mahmud; Michelle Guy; Lynne T O'Brien; Rosemary A Wilkinson; Amanda L Hall; Emma J Sawyer; Tokhir Dadaev; Jonathan Morrison; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin S Cooper; Aritaya Lophatonanon; Melissa C Southey; John L Hopper; Dallas R English; Tiina Wahlfors; Teuvo L J Tammela; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Anne Tybjærg-Hansen; Stig E Bojesen; Ruth Travis; Federico Canzian; Rudolf Kaaks; Fredrik Wiklund; Markus Aly; Sara Lindstrom; W Ryan Diver; Susan Gapstur; Mariana C Stern; Roman Corral; Jarmo Virtamo; Angela Cox; Christopher A Haiman; Loic Le Marchand; Liesel Fitzgerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; Torben Falck Orntoft; Michael Borre; Andreas Meyer; Jürgen Serth; Meredith Yeager; Sonja I Berndt; James R Marthick; Briony Patterson; Dominika Wokolorczyk; Jyotsna Batra; Felicity Lose; Shannon K McDonnell; Amit D Joshi; Ahva Shahabi; Antje E Rinckleb; Ana Ray; Thomas A Sellers; Hui-Yi Lin; Robert A Stephenson; James Farnham; Heiko Muller; Dietrich Rothenbacher; Norihiko Tsuchiya; Shintaro Narita; Guang-Wen Cao; Chavdar Slavov; Vanio Mitev; Douglas F Easton; Rosalind A Eeles Journal: Nat Genet Date: 2011-07-10 Impact factor: 38.330
Authors: Sarah J Lewis; Ali Murad; Lina Chen; George Davey Smith; Jenny Donovan; Tom Palmer; Freddie Hamdy; David Neal; J Athene Lane; Michael Davis; Angela Cox; Richard M Martin Journal: PLoS One Date: 2010-10-19 Impact factor: 3.240
Authors: Roland B Walter; Theodore M Brasky; Sarah A Buckley; John D Potter; Emily White Journal: J Natl Cancer Inst Date: 2013-05-24 Impact factor: 13.506
Authors: Rebecca E Graff; Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Kathryn L Penney; Kathryn M Wilson; Sarah C Markt; Claire H Pernar; Amparo G Gonzalez-Feliciano; Mingyang Song; Rosina T Lis; Daniel R Schmidt; Matthew G Vander Heiden; Michelangelo Fiorentino; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-22 Impact factor: 4.254